Cornelia Landersdorfer

Author Archive | Cornelia Landersdorfer

Population modelling of lithium in paediatric patients with bipolar disorder: implications for dosing

Introduction. Bipolar I disorder (BP-I) leads to substantive psychosocial dysfunction. Lithium is well-established for treating BP-I in adults, however there is a paucity of information in paediatrics. Aims. To characterise the pharmacokinetics/pharmacodynamics (PK/PD) of lithium in paediatrics and to predict lithium concentrations and clinical effects for novel dosage regimens. Methods. Observed lithium concentrations and Young […]

Continue Reading

Population pharmacokinetics of colistin and its prodrug colistin methanesulfonate following intravenous and pulmonary dosing in sheep

Background. Colistin is administered as its inactive prodrug colistin methanesulfonate (CMS) and is increasingly used as last-line therapy against multidrug-resistant Gram-negative bacteria. While pulmonary dosing of CMS is utilised in lung infections to reduce the risk of nephrotoxicity and neurotoxicity, there is a dearth of pharmacokinetic (PK) information on colistin and CMS. Quantitatively characterising the […]

Continue Reading

Mechanism-based modelling and sequential dosing to elucidate subpopulation synergy for antibiotic combinations

Background: Rational and prospective approaches to optimize antibiotic combination therapy are scarce. Due to the emerging global healthcare crisis caused by multidrug-resistant bacteria, more efficient and quantitative approaches to optimize combination therapy are urgently required. Nisin, a peptide antibiotic affecting pore formation in bacterial membranes and preventing peptidoglycan synthesis, is rapidly bactericidal against multiple-resistant Staphylococcus […]

Continue Reading

Population Modelling of Vildagliptin as an Inhibitor and Substrate of Dipeptidylpeptidase IV and its Effects on Glucagon-Like Peptide 1, Glucose, and Insulin

Background. Vildagliptin acts by inhibiting dipeptidyl peptidase IV (DPP-4), thereby increases active GLP-1 (glucagon-like peptide 1) concentrations and decreases plasma glucose in diabetic patients. Objectives. To develop a mechanism-based population PK/PD model that simultaneously describes and predicts vildagliptin pharmacokinetics and its effects on DPP-4 activity and the underlying glucose-insulin-GLP-1 system. Methods. Data used for model […]

Continue Reading